Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequen...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
07 January 2021
|
| In: |
Blood cancer journal
Year: 2021, Volume: 11, Pages: 1-10 |
| ISSN: | 2044-5385 |
| DOI: | 10.1038/s41408-020-00390-3 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41408-020-00390-3 Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41408-020-00390-3 
|
| Author Notes: | Marc-Andrea Baertsch, Elias K. Mai, Thomas Hielscher, Uta Bertsch, Hans J. Salwender, Markus Munder, Stephan Fuhrmann, Ulrich Dührsen, Peter Brossart, Kai Neben, Jana Schlenzka, Christina Kunz, Marc S. Raab, Jens Hillengaß, Anna Jauch, Anja Seckinger, Dirk Hose, Steffen Luntz, Pieter Sonneveld, Henk Lokhorst, Hans Martin, Martin Goerner, Martin Hoffmann, Hans-Walter Lindemann, Helga Bernhard, Igor W. Blau, Christof Scheid, Britta Besemer, Katja C. Weisel, Mathias Hänel, Jan Dürig, Hartmut Goldschmidt, German-Speaking MyelomaMulticenter Group (GMMG) |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1751046923 | ||
| 003 | DE-627 | ||
| 005 | 20241230004411.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210310s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41408-020-00390-3 |2 doi | |
| 035 | |a (DE-627)1751046923 | ||
| 035 | |a (DE-599)KXP1751046923 | ||
| 035 | |a (OCoLC)1341398393 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bärtsch, Marc-Andrea |d 1988- |e VerfasserIn |0 (DE-588)1099464854 |0 (DE-627)858599074 |0 (DE-576)469306505 |4 aut | |
| 245 | 1 | 0 | |a Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma |c Marc-Andrea Baertsch, Elias K. Mai, Thomas Hielscher, Uta Bertsch, Hans J. Salwender, Markus Munder, Stephan Fuhrmann, Ulrich Dührsen, Peter Brossart, Kai Neben, Jana Schlenzka, Christina Kunz, Marc S. Raab, Jens Hillengaß, Anna Jauch, Anja Seckinger, Dirk Hose, Steffen Luntz, Pieter Sonneveld, Henk Lokhorst, Hans Martin, Martin Goerner, Martin Hoffmann, Hans-Walter Lindemann, Helga Bernhard, Igor W. Blau, Christof Scheid, Britta Besemer, Katja C. Weisel, Mathias Hänel, Jan Dürig, Hartmut Goldschmidt, German-Speaking MyelomaMulticenter Group (GMMG) |
| 264 | 1 | |c 07 January 2021 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.03.2021 | ||
| 520 | |a Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequent GMMG phase III trials. All patients received three cycles of BTZ-based triplet induction and post-ASCT MT. BTZ MT (1.3 mg/m2 i.v.) was administered every 2 weeks for 2 years. LEN MT included two consolidation cycles (25 mg p.o., days 1-21 of 28 day cycles) followed by 10-15 mg/day for 2 years. The BTZ cohort more frequently received tandem ASCT (91% vs. 33%) due to different tandem ASCT strategies. In the LEN and BTZ cohort, 43% and 46% of patients completed 2 years of MT as intended (p = 0.57). Progression-free survival (PFS; HR = 0.83, p = 0.18) and overall survival (OS; HR = 0.70, p = 0.15) did not differ significantly with LEN vs. BTZ MT. Patients with <nCR after first ASCT were assigned tandem ASCT in both trials. In patients with <nCR and tandem ASCT (LEN: n = 54 vs. BTZ: n = 84), LEN MT significantly improved PFS (HR = 0.61, p = 0.04) but not OS (HR = 0.46, p = 0.09). In conclusion, the significant PFS benefit after eliminating the impact of different tandem ASCT rates supports the current standard of LEN MT after ASCT. | ||
| 700 | 1 | |a Mai, Elias K. |d 1985- |e VerfasserIn |0 (DE-588)1049182545 |0 (DE-627)781300274 |0 (DE-576)403130999 |4 aut | |
| 700 | 1 | |a Hielscher, Thomas |e VerfasserIn |0 (DE-588)1159594791 |0 (DE-627)1022977768 |0 (DE-576)50506068X |4 aut | |
| 700 | 1 | |a Bertsch, Uta |e VerfasserIn |0 (DE-588)1026849861 |0 (DE-627)727494163 |0 (DE-576)372176224 |4 aut | |
| 700 | 1 | |a Salwender, Hans J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Munder, Markus |d 1967- |e VerfasserIn |0 (DE-588)121183610 |0 (DE-627)705288188 |0 (DE-576)292574347 |4 aut | |
| 700 | 1 | |8 1\p |a Fuhrmann, Stephan |d 1979- |e VerfasserIn |0 (DE-588)13644654X |0 (DE-627)583293417 |0 (DE-576)301024693 |4 aut | |
| 700 | 1 | |8 2\p |a Dührsen, Ulrich |e VerfasserIn |0 (DE-588)1073185001 |0 (DE-627)828638543 |0 (DE-576)434686611 |4 aut | |
| 700 | 1 | |8 3\p |a Brossart, Peter |e VerfasserIn |0 (DE-588)1171862997 |0 (DE-627)1040747183 |0 (DE-576)513889558 |4 aut | |
| 700 | 1 | |a Neben, Kai |d 1969- |e VerfasserIn |0 (DE-588)120842181 |0 (DE-627)080920470 |0 (DE-576)292411774 |4 aut | |
| 700 | 1 | |a Schlenzka, Jana |d 1971- |e VerfasserIn |0 (DE-588)122728513 |0 (DE-627)70601782X |0 (DE-576)293397163 |4 aut | |
| 700 | 1 | |a Kunz, Christina |e VerfasserIn |0 (DE-588)1206902620 |0 (DE-627)1693152258 |4 aut | |
| 700 | 1 | |a Raab, Marc-Steffen |d 1973- |e VerfasserIn |0 (DE-588)124052460 |0 (DE-627)706520998 |0 (DE-576)293998027 |4 aut | |
| 700 | 1 | |a Hillengaß, Jens |d 1974- |e VerfasserIn |0 (DE-588)124918549 |0 (DE-627)368073823 |0 (DE-576)294568298 |4 aut | |
| 700 | 1 | |a Jauch, Anna |d 1959- |e VerfasserIn |0 (DE-588)1025525140 |0 (DE-627)722525362 |0 (DE-576)168357496 |4 aut | |
| 700 | 1 | |a Seckinger, Anja |d 1980- |e VerfasserIn |0 (DE-588)134177371 |0 (DE-627)562118225 |0 (DE-576)278603734 |4 aut | |
| 700 | 1 | |a Hose, Dirk |d 1969- |e VerfasserIn |0 (DE-588)139824995 |0 (DE-627)613790308 |0 (DE-576)313431698 |4 aut | |
| 700 | 1 | |a Luntz, Steffen P. |d 1968- |e VerfasserIn |0 (DE-588)120890216 |0 (DE-627)70506624X |0 (DE-576)292433077 |4 aut | |
| 700 | 1 | |a Sonneveld, Pieter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lokhorst, Henk |e VerfasserIn |4 aut | |
| 700 | 1 | |a Martin, Hans |e VerfasserIn |4 aut | |
| 700 | 1 | |8 4\p |a Görner, Martin |d 1964- |e VerfasserIn |0 (DE-588)130475378 |0 (DE-627)707497817 |0 (DE-576)298218909 |4 aut | |
| 700 | 1 | |a Hoffmann, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lindemann, Hans-Walter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bernhard, Helga |e VerfasserIn |4 aut | |
| 700 | 1 | |a Blau, Igor-Wolfgang |d 1960- |e VerfasserIn |0 (DE-588)111826438 |0 (DE-627)566073560 |0 (DE-576)289713366 |4 aut | |
| 700 | 1 | |a Scheid, Christoph |e VerfasserIn |0 (DE-588)1075475244 |0 (DE-627)833299670 |0 (DE-576)443494495 |4 aut | |
| 700 | 1 | |8 5\p |a Besemer, Britta |d 1982- |e VerfasserIn |0 (DE-588)143883828 |0 (DE-627)655894675 |0 (DE-576)33951518X |4 aut | |
| 700 | 1 | |8 6\p |a Weisel, Katja |d 1971- |e VerfasserIn |0 (DE-588)118014935 |0 (DE-627)079191975 |0 (DE-576)291668887 |4 aut | |
| 700 | 1 | |a Hänel, Mathias |d 1964- |e VerfasserIn |0 (DE-588)17362295X |0 (DE-627)698532414 |0 (DE-576)134465970 |4 aut | |
| 700 | 1 | |8 7\p |a Dürig, Jan |e VerfasserIn |0 (DE-588)1167428412 |0 (DE-627)103110268X |0 (DE-576)511135750 |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood cancer journal |d [London] : Springer Nature, 2011 |g 11(2021), Artikel-ID 1, Seite 1-10 |h Online-Ressource |w (DE-627)655134174 |w (DE-600)2600560-8 |w (DE-576)339571802 |x 2044-5385 |7 nnas |a Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g elocationid:1 |g pages:1-10 |g extent:10 |a Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41408-020-00390-3 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41408-020-00390-3 |x Verlag |z kostenfrei |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 2\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 3\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 4\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 5\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 6\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 7\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20210310 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 32 |y j | ||
| 998 | |g 120890216 |a Luntz, Steffen P. |m 120890216:Luntz, Steffen P. |d 910000 |d 913000 |e 910000PL120890216 |e 913000PL120890216 |k 0/910000/ |k 1/910000/913000/ |p 18 | ||
| 998 | |g 139824995 |a Hose, Dirk |m 139824995:Hose, Dirk |d 50000 |e 50000PH139824995 |k 0/50000/ |p 17 | ||
| 998 | |g 134177371 |a Seckinger, Anja |m 134177371:Seckinger, Anja |p 16 | ||
| 998 | |g 1025525140 |a Jauch, Anna |m 1025525140:Jauch, Anna |d 910000 |d 911500 |e 910000PJ1025525140 |e 911500PJ1025525140 |k 0/910000/ |k 1/910000/911500/ |p 15 | ||
| 998 | |g 124918549 |a Hillengaß, Jens |m 124918549:Hillengaß, Jens |d 50000 |e 50000PH124918549 |k 0/50000/ |p 14 | ||
| 998 | |g 124052460 |a Raab, Marc-Steffen |m 124052460:Raab, Marc-Steffen |d 910000 |d 910100 |e 910000PR124052460 |e 910100PR124052460 |k 0/910000/ |k 1/910000/910100/ |p 13 | ||
| 998 | |g 1206902620 |a Kunz, Christina |m 1206902620:Kunz, Christina |d 50000 |e 50000PK1206902620 |k 0/50000/ |p 12 | ||
| 998 | |g 122728513 |a Schlenzka, Jana |m 122728513:Schlenzka, Jana |d 910000 |d 910100 |e 910000PS122728513 |e 910100PS122728513 |k 0/910000/ |k 1/910000/910100/ |p 11 | ||
| 998 | |g 120842181 |a Neben, Kai |m 120842181:Neben, Kai |d 50000 |e 50000PN120842181 |k 0/50000/ |p 10 | ||
| 998 | |g 1026849861 |a Bertsch, Uta |m 1026849861:Bertsch, Uta |d 910000 |d 910100 |e 910000PB1026849861 |e 910100PB1026849861 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 1159594791 |a Hielscher, Thomas |m 1159594791:Hielscher, Thomas |d 140000 |e 140000PH1159594791 |k 0/140000/ |p 3 | ||
| 998 | |g 1049182545 |a Mai, Elias K. |m 1049182545:Mai, Elias K. |d 910000 |d 910100 |e 910000PM1049182545 |e 910100PM1049182545 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 1099464854 |a Bärtsch, Marc-Andrea |m 1099464854:Bärtsch, Marc-Andrea |d 910000 |d 910100 |e 910000PB1099464854 |e 910100PB1099464854 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1751046923 |e 3884288083 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"07 January 2021"}],"note":["Gesehen am 10.03.2021"],"title":[{"title_sort":"Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma","title":"Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"person":[{"role":"aut","given":"Marc-Andrea","family":"Bärtsch","display":"Bärtsch, Marc-Andrea"},{"given":"Elias K.","role":"aut","family":"Mai","display":"Mai, Elias K."},{"role":"aut","given":"Thomas","display":"Hielscher, Thomas","family":"Hielscher"},{"display":"Bertsch, Uta","family":"Bertsch","role":"aut","given":"Uta"},{"display":"Salwender, Hans J.","family":"Salwender","role":"aut","given":"Hans J."},{"role":"aut","given":"Markus","display":"Munder, Markus","family":"Munder"},{"family":"Fuhrmann","display":"Fuhrmann, Stephan","given":"Stephan","role":"aut"},{"role":"aut","given":"Ulrich","family":"Dührsen","display":"Dührsen, Ulrich"},{"given":"Peter","role":"aut","family":"Brossart","display":"Brossart, Peter"},{"role":"aut","given":"Kai","display":"Neben, Kai","family":"Neben"},{"given":"Jana","role":"aut","display":"Schlenzka, Jana","family":"Schlenzka"},{"given":"Christina","role":"aut","display":"Kunz, Christina","family":"Kunz"},{"role":"aut","given":"Marc-Steffen","display":"Raab, Marc-Steffen","family":"Raab"},{"role":"aut","given":"Jens","family":"Hillengaß","display":"Hillengaß, Jens"},{"family":"Jauch","display":"Jauch, Anna","role":"aut","given":"Anna"},{"role":"aut","given":"Anja","display":"Seckinger, Anja","family":"Seckinger"},{"role":"aut","given":"Dirk","family":"Hose","display":"Hose, Dirk"},{"role":"aut","given":"Steffen P.","family":"Luntz","display":"Luntz, Steffen P."},{"display":"Sonneveld, Pieter","family":"Sonneveld","role":"aut","given":"Pieter"},{"given":"Henk","role":"aut","family":"Lokhorst","display":"Lokhorst, Henk"},{"family":"Martin","display":"Martin, Hans","given":"Hans","role":"aut"},{"display":"Görner, Martin","family":"Görner","given":"Martin","role":"aut"},{"family":"Hoffmann","display":"Hoffmann, Martin","given":"Martin","role":"aut"},{"display":"Lindemann, Hans-Walter","family":"Lindemann","given":"Hans-Walter","role":"aut"},{"display":"Bernhard, Helga","family":"Bernhard","given":"Helga","role":"aut"},{"given":"Igor-Wolfgang","role":"aut","display":"Blau, Igor-Wolfgang","family":"Blau"},{"family":"Scheid","display":"Scheid, Christoph","role":"aut","given":"Christoph"},{"display":"Besemer, Britta","family":"Besemer","role":"aut","given":"Britta"},{"role":"aut","given":"Katja","display":"Weisel, Katja","family":"Weisel"},{"family":"Hänel","display":"Hänel, Mathias","role":"aut","given":"Mathias"},{"given":"Jan","role":"aut","family":"Dürig","display":"Dürig, Jan"},{"display":"Goldschmidt, Hartmut","family":"Goldschmidt","role":"aut","given":"Hartmut"}],"id":{"eki":["1751046923"],"doi":["10.1038/s41408-020-00390-3"]},"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"recId":"655134174","pubHistory":["1.2011-"],"id":{"eki":["655134174"],"issn":["2044-5385"],"zdb":["2600560-8"]},"disp":"Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myelomaBlood cancer journal","part":{"year":"2021","text":"11(2021), Artikel-ID 1, Seite 1-10","pages":"1-10","extent":"10","volume":"11"},"origin":[{"dateIssuedKey":"2017","publisher":"Springer Nature ; Nature Publ. Group","publisherPlace":"[London] ; London [u.a.]","dateIssuedDisp":"2017-"}],"note":["Gesehen am 17.07.24"],"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title":"Blood cancer journal","title_sort":"Blood cancer journal"}],"language":["eng"]}],"physDesc":[{"extent":"10 S."}],"name":{"displayForm":["Marc-Andrea Baertsch, Elias K. Mai, Thomas Hielscher, Uta Bertsch, Hans J. Salwender, Markus Munder, Stephan Fuhrmann, Ulrich Dührsen, Peter Brossart, Kai Neben, Jana Schlenzka, Christina Kunz, Marc S. Raab, Jens Hillengaß, Anna Jauch, Anja Seckinger, Dirk Hose, Steffen Luntz, Pieter Sonneveld, Henk Lokhorst, Hans Martin, Martin Goerner, Martin Hoffmann, Hans-Walter Lindemann, Helga Bernhard, Igor W. Blau, Christof Scheid, Britta Besemer, Katja C. Weisel, Mathias Hänel, Jan Dürig, Hartmut Goldschmidt, German-Speaking MyelomaMulticenter Group (GMMG)"]},"recId":"1751046923"} | ||
| SRT | |a BAERTSCHMALENALIDOMI0720 | ||